LEXICON PHARMACEUTICALS INC (LXRX)
US5288723027 - Common Stock
LXRX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 577 industry peers in the Biotechnology industry. The financial health of LXRX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, LXRX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year LXRX has reported negative net income.
In the past year LXRX has reported a negative cash flow from operations.
In the past 5 years LXRX reported 4 times negative net income.
In the past 5 years LXRX reported 4 times negative operating cash flow.
1.2 Ratios
LXRX has a Return On Assets (-46.39%) which is in line with its industry peers.
LXRX has a Return On Equity of -67.00%. This is comparable to the rest of the industry: LXRX outperforms 55.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.39% | ||
| ROE | -67% | ||
| ROIC | N/A |
ROA(3y)-64.59%
ROA(5y)-38.28%
ROE(3y)-118.18%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 95.67%, LXRX belongs to the best of the industry, outperforming 96.17% of the companies in the same industry.
In the last couple of years the Gross Margin of LXRX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for LXRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.67% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y-0.65%
2. Health
2.1 Basic Checks
LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LXRX has been increased compared to 1 year ago.
The number of shares outstanding for LXRX has been increased compared to 5 years ago.
The debt/assets ratio for LXRX is higher compared to a year ago.
2.2 Solvency
LXRX has an Altman-Z score of -2.64. This is a bad value and indicates that LXRX is not financially healthy and even has some risk of bankruptcy.
LXRX has a Altman-Z score (-2.64) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.35 indicates that LXRX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.35, LXRX is doing worse than 70.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.64 |
ROIC/WACCN/A
WACC11.11%
2.3 Liquidity
A Current Ratio of 15.58 indicates that LXRX has no problem at all paying its short term obligations.
LXRX's Current ratio of 15.58 is amongst the best of the industry. LXRX outperforms 88.68% of its industry peers.
A Quick Ratio of 15.56 indicates that LXRX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 15.56, LXRX belongs to the best of the industry, outperforming 88.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.58 | ||
| Quick Ratio | 15.56 |
3. Growth
3.1 Past
The earnings per share for LXRX have decreased strongly by -33.87% in the last year.
Looking at the last year, LXRX shows a very strong growth in Revenue. The Revenue has grown by 1104.00%.
LXRX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -54.71% yearly.
EPS 1Y (TTM)-33.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.65%
Revenue 1Y (TTM)1104%
Revenue growth 3Y-63.12%
Revenue growth 5Y-54.71%
Sales Q2Q%4608.33%
3.2 Future
LXRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.06% yearly.
The Revenue is expected to grow by 222.40% on average over the next years. This is a very strong growth
EPS Next Y2.51%
EPS Next 2Y6.09%
EPS Next 3Y15.2%
EPS Next 5Y30.06%
Revenue Next Year1283.35%
Revenue Next 2Y592.92%
Revenue Next 3Y367.49%
Revenue Next 5Y222.4%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
LXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LXRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LXRX's earnings are expected to grow with 15.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.09%
EPS Next 3Y15.2%
5. Dividend
5.1 Amount
LXRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LEXICON PHARMACEUTICALS INC
NASDAQ:LXRX (7/26/2024, 7:00:00 PM)
After market: 2.4 +0.01 (+0.42%)2.39
+0.06 (+2.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap863.84M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.39% | ||
| ROE | -67% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.67% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 15.58 | ||
| Quick Ratio | 15.56 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-33.87%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y2.51%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1104%
Revenue growth 3Y-63.12%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y